A Stanford-led team has replaced toxic pre-transplant chemotherapy with a targeted antibody, allowing children with Fanconi anemia to receive stem cell transplants safely. The antibody, briquilimab, removes diseased stem cells without radiation, enabling nearly complete donor cell replacement. The approach also widens donor eligibility and could soon be applied to other bone marrow failure diseases.
source https://www.sciencedaily.com/releases/2025/11/251107010324.htm
The COVID‑19 pandemic exposed the load mothers carry—a burden that's still
being ignored today
-
The COVID-19 pandemic exacerbated and brought into focus the ongoing
disproportionate burden on mothers when it comes to household logistics,
child care an...
2 days ago
Welcome to the 'The Fact Factory' friends. Its an interesting Hot Spot which brings to you amazing and little known facts from all over the world. So, sit back, take a tour around the world and enjoy the trivia.
No comments:
Post a Comment